Consultation Paper on Drug Registry: NHA
Recently the National Health Authority (NHA) has invited comments on the “Consultation Paper related to Drug Registry”.
- The Drug Registry was envisaged under the Ayushman Bharat Digital Mission (ABDM). This registry will be in the form of a single, updated, and nationally recognized registry of all medicines.
- ABDM has been launched to build a national digital health ecosystem. This ecosystem aims to support Universal Health Coverage in an efficient, accessible, inclusive, economical, timely and safe manner.
Registry:
- It is one of the basic sections of ABDM. It is a secure repository of different types of data (health related facilities, health care professionals, etc.). Under this, users can voluntarily enroll.
- This drug registry will act as a centralized repository (or repository) of all medicines related to all systems of medicine (from Allopathic to Ayurveda). These drugs will include drugs approved in the Indian market and available in the Indian market.
- Currently, different authorities or departments collect data based on different stages of the product’s life cycle. Hence there is a lack of a central database for the drugs sold in the market.
- This will help in standardization of health care data.
Other benefits:
- It will ensure free availability of verified information for all medicines,
- It will encourage simplified regulatory process,
- It will promote smooth supply chain management,
- It will streamline the insurance claim processes,
- It will encourage innovation in clinical decisions, disease management etc.
National Health Authority (NHA)
- It is the apex body responsible for implementing Ayushman Bharat Pradhan Mantri Jan Arogya Yojana, and ABDM.
- The NHA is governed by a governing board headed by the Union Minister of Health and Family Welfare.
Source – The Hindu
